ACOG

Alpha Cognition Inc. is a Canadian biopharmaceutical company focused on developing novel therapies for neurological diseases, with a primary emphasis on Alzheimer's disease and other cognitive disorders. Headquartered in Vancouver, British Columbia, the company operates through its development and commercialization of pharmaceutical treatments targeting underserved patient populations. Alpha Cognition's lead product candidate is ZUNVEYL (benzgalantamine), a patented formulation designed to improve upon existing acetylcholinesterase inhibitors for Alzheimer's treatment. The company received FDA approval for ZUNVEYL in June 2023, marking a significant milestone as it transitioned from a clinical-stage to a commercial-stage enterprise. Alpha Cognition trades on the NASDAQ under the ticker symbol ACOG and on the Toronto Stock Exchange as ACOG. The company focuses its commercial strategy on the United States market, where it launched ZUNVEYL through partnerships with specialty pharmacies and healthcare providers. In addition to its Alzheimer's program, Alpha Cognition maintains a pipeline of earlier-stage neurological programs. The company operates with a lean structure typical of emerging biopharmaceutical firms, prioritizing research and development investments alongside its newly established commercial operations. As a development-stage company, Alpha Cognition continues to balance product commercialization activities with ongoing clinical research and regulatory initiatives to support its growth trajectory in the neurodegenerative disease treatment market.